JTCS St. Jude Medical
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Martin Strüber
Stefan Fischer
Gregor Warnecke
Axel Haverich
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strüber, M.
Right arrow Articles by Hohlfeld, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strüber, M.
Right arrow Articles by Hohlfeld, J. M.
Related Collections
Right arrow Lung - transplantation
Right arrow Cardiac - physiology
Right arrow Mechanical Circulatory Assistance
Right arrow Molecular biology
Right arrow Transplantation - heart

J Thorac Cardiovasc Surg 2007;133:1620-1625
© 2007 The American Association for Thoracic Surgery


Cardiothoracic Transplantation

Effects of exogenous surfactant instillation in clinical lung transplantation: A prospective, randomized trial

Martin Strüber, MDa,*, Stefan Fischer, MD, MSca, Jost Niedermeyer, MDb, Gregor Warnecke, MDa, Bernhard Gohrbandt, MDa, Adelheid Görler, MDa, Andre R. Simon, MDa, Axel Haverich, MDa, Jens M. Hohlfeld, MDb

a Hannover Thoracic Transplant Program, Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany
b Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.

Received for publication April 11, 2006; revisions received December 10, 2006; accepted for publication December 14, 2006.

* Address for reprints: Martin Strüber, MD, Director, Hannover Thoracic Transplant Program, Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Carl Neuberg Strasse 1, 30625 Hannover, Germany. (Email: strueber.martin{at}mh-hannover.de).

Objective: Despite the introduction of low potassium–based preservation strategies for clinical lung transplantation, relevant early graft dysfunction occurs in up to 20% of cases after lung transplantation. This was found to be frequently associated with postreperfusion surfactant dysfunction. We performed a randomized, prospective study investigating the effect of exogenous surfactant instillation into human donor lungs on posttransplant surfactant function and on clinical outcome.

Methods: Exogenous surfactant was instilled into 15 donor lungs before retrieval via bronchoscopy. Bronchoalveolar lavage fluids were taken before instillation as well as 24 hours after transplantation. Surfactant function, phospholipids, and protein content in bronchoalveolar lavage fluids were assessed and clinical data prospectively recorded. Pulmonary function testing was performed 4 weeks after lung transplantation. Additionally, the best forced expiratory volume in 1 second was determined within the first year after lung transplantation. The control group consisted of 14 patients receiving donor lungs without surfactant instillation in randomized order. Pulmonary function test results were further compared with those of 154 consecutive recipients of bilateral lung transplants, which were not involved in the study (historical control).

Results: No deaths occurred during the first year after lung transplantation. Surfactant function in donor lungs was within normal ranges before harvest. In the control group, surfactant function was markedly impaired after reperfusion. This was significantly improved by surfactant substitution. Protein content of the bronchoalveolar lavage fluid in the surfactant group was significantly lower, indicating less leakage through the alveolocapillary membrane. Forced expiratory volume in 1 second after 4 weeks was significantly higher in the surfactant group than in either control group (P = .034 and .01, respectively). Interestingly, the best forced expiratory volume in 1 second during the first year after lung transplantation was significantly higher in both control groups compared with forced expiratory volume measured in examinations 4 weeks after lung transplantation (P = .01). The best forced expiratory volumes in 1 second of control patients were comparable with those in surfactant lungs 4 weeks after transplant.

Conclusions: This study indicates a protective effect of exogenous surfactant instillation to donor lungs before retrieval on post–lung transplantation surfactant function and on early clinical outcome. This approach may help to improve the outcome after lung transplantation in the future.



Abbreviations and Acronyms BAL = bronchoalveolar lavage; BALF = bronchoalveolar lavage fluid; FEV1 = forced expiratory volume in 1 second; {gamma}min = minimal surface tension; LPD = low-potassium dextran; SA/LA = small-to-large aggregates ratio





This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
P. A. Corris and J. D. Christie
Update in Transplantation 2007
Am. J. Respir. Crit. Care Med., May 15, 2008; 177(10): 1062 - 1067.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 by The American Association for Thoracic Surgery.